MedTrace Logo

A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects

NCT04973189 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2023-05-18

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous administration of SHR-1707 in healthy young adult and elderly subjects.

Conditions

Interventions

DRUG

SHR-1707

A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.

DRUG

Placebo

A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.

DRUG

SHR-1707

A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.

DRUG

Placebo

A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-08
Primary Completion
2022-01-13
Completion
2022-01-13

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04973189 on ClinicalTrials.gov